Tian Zhang, MD

Articles

Dr. Zhang on Emerging Biomarkers of Response to Immunotherapy in RCC

March 1st 2021

Tian Zhang, MD, discusses emerging biomarkers that are helping to guide treatment for patients with renal cell carcinoma.

Dr. Zhang on the PDIGREE Trial Examining Nivolumab/Ipilimumab Plus Cabozantinib in Metastatic RCC

February 11th 2021

Tian Zhang, MD, discusses the goal of the ongoing PDIGREE trial examining nivolumab and ipilimumab plus cabozantinib in patients with metastatic untreated renal cell cancer.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 12th 2019

Tian Zhang, MD, discusses data from the randomized phase III IMvigor130 trial, which compared the safety and efficacy of atezolizumab in combination with platinum-based chemotherapy, atezolizumab monotherapy, and chemotherapy alone, in the frontline treatment of patients with metastatic urothelial cancer.

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

January 25th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

Dr. Zhang on Toxicities of Treatments in RCC

January 9th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC

January 3rd 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC

December 8th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Dr. Zhang on the ARCHES Trial in Prostate Cancer

December 1st 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.